Average cost of drugs for extensively drug-resistant tuberculosis in Kazakhstan
Kazakhstan: Average cost of drugs for extensively drug-resistant tuberculosis was 6,329 constant 2022 US$ in 2023. ▲ Rising
Average cost of drugs for extensively drug-resistant tuberculosis in Kazakhstan, 2017–2023
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
Kazakhstan recorded 6,329 constant 2022 US$ for average cost of drugs for extensively drug-resistant tuberculosis in 2023. That is the highest value across all 7 years on record.
That represents a change of up 14.5% on the previous year and up 62.2% over ten years.
Kazakhstan ranks 5th of 56 countries on this measure, in the top 10%.
Average cost of drugs for extensively drug-resistant tuberculosis in Kazakhstan, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 3,903 constant 2022 US$ | — |
| 2018 | 2,881 constant 2022 US$ | -26.2% |
| 2019 | 4,830 constant 2022 US$ | +67.7% |
| 2020 | 3,500 constant 2022 US$ | -27.5% |
| 2021 | 3,867 constant 2022 US$ | +10.5% |
| 2022 | 5,526 constant 2022 US$ | +42.9% |
| 2023 | 6,329 constant 2022 US$ | +14.5% |
Kazakhstan compared with similar countries
- Kazakhstan's 6,329 constant 2022 US$ is above the median for upper middle income countries, which is 2,000 constant 2022 US$, 3.2× the median. (23 countries reporting)
- Kazakhstan's 6,329 constant 2022 US$ is above the median for Europe & Central Asia, which is 4,345 constant 2022 US$, 1.5× the median. (8 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 3,871 constant 2022 US$ | 2,881 constant 2022 US$ | 4,830 constant 2022 US$ | 3 |
| 2020s | 4,806 constant 2022 US$ | 3,500 constant 2022 US$ | 6,329 constant 2022 US$ | 4 |
Countries ranked near Kazakhstan
More reference data data for Kazakhstan
- Emission Totals - Indirect emissions (N2O) - Manure applied to Soils 1.3 (2050)
- Emission Totals - Indirect emissions (N2O) - Manure left on Pasture 2.52 (2050)
- Emission Totals - Indirect emissions (N2O) - IPCC Agriculture 4.95 (2050)
- Emission Totals - Indirect emissions (N2O) - Crop Residues 0.8607 (2050)
- Emission Totals - Indirect emissions (N2O) - Agricultural Soils 4.95 (2050)
- Emission Totals - Emissions (N2O) - Manure applied to Soils 4.36 (2050)
- Emission Totals - Emissions (N2O) - Manure Management 4.63 (2050)
- Emission Totals - Emissions (N2O) - Manure left on Pasture 10.75 (2050)
- Emission Totals - Emissions (N2O) - IPCC Agriculture 25.76 (2050)
- Emission Totals - Emissions (N2O) - Crop Residues 4.69 (2050)
Frequently asked questions
- What is average cost of drugs for extensively drug-resistant tuberculosis in Kazakhstan?
- Average cost of drugs for extensively drug-resistant tuberculosis in Kazakhstan was 6,329 constant 2022 US$ in 2023, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of drugs for extensively drug-resistant tuberculosis recorded in Kazakhstan?
- The highest recorded value was 6,329 constant 2022 US$ in 2023.
- What is the lowest average cost of drugs for extensively drug-resistant tuberculosis recorded in Kazakhstan?
- The lowest recorded value was 2,881 constant 2022 US$ in 2018.
- How does Kazakhstan rank for average cost of drugs for extensively drug-resistant tuberculosis?
- Kazakhstan ranks 5th out of 56 countries with data for 2023.
- Is average cost of drugs for extensively drug-resistant tuberculosis rising or falling in Kazakhstan?
- Over the last ten years it is up 62.2%. The long-run trend across the full record is rising.
- Where does this Kazakhstan data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 7 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.